|
30/10/2025
|
07:00
|
G308 Phase III Year 2 Patient Screening Starts
|
RNS
|
|
29/10/2025
|
07:00
|
Warrant Exercise and Paydown of Debt
|
RNS
|
|
16/10/2025
|
07:00
|
Further progress in Phase I/IIa PROTECT trial
|
RNS
|
|
31/07/2025
|
07:00
|
Grass MATA MPL Publications in Allergy Journal
|
RNS
|
|
21/07/2025
|
07:00
|
Trading update for the year ended 30 June 2025
|
RNS
|
|
11/07/2025
|
07:00
|
PDMR Dealings
|
RNS
|
|
13/06/2025
|
07:00
|
Allergy Therapeutics presents findings at EAACI
|
RNS
|
|
10/06/2025
|
07:04
|
EAACI Early Career Research Award
|
RNS
|
|
31/03/2025
|
07:00
|
Interim Results for six months ended 31 Dec 2024
|
RNS
|
|
27/03/2025
|
07:00
|
Advancement to final phase of PROTECT trial
|
RNS
|
|
03/03/2025
|
07:00
|
New Executive Long Term Incentive Awards
|
RNS
|
|
27/02/2025
|
07:00
|
Presentations at 2025 AAAAI / WAO Joint Congress
|
RNS
|
|
17/02/2025
|
07:00
|
Grass MATA MPL Phase III data published in Allergy
|
RNS
|
|
14/02/2025
|
07:00
|
Grant of Options
|
RNS
|
|
28/01/2025
|
07:00
|
Half Year Trading update
|
RNS
|
|
22/01/2025
|
07:00
|
PDMR Dealing and Total Voting Rights
|
RNS
|
|
15/01/2025
|
07:00
|
Director/PDMR Shareholding
|
RNS
|
|
19/12/2024
|
13:41
|
Exercise of Options and Total Voting Rights
|
RNS
|
|
17/12/2024
|
16:19
|
Block Listing Interim Review
|
RNS
|
|
16/12/2024
|
15:33
|
Result of Annual General Meeting
|
RNS
|
|
04/12/2024
|
07:00
|
Positive Interim Data from PROTECT Trial
|
RNS
|
|
27/11/2024
|
07:00
|
First Patient Dosed in G308 Paediatric Trial
|
RNS
|
|
25/11/2024
|
07:00
|
Submission of MAA for Grass MATA MPL
|
RNS
|
|
21/11/2024
|
07:00
|
Notice of 2024 Annual General Meeting
|
RNS
|
|
06/11/2024
|
07:00
|
Audited Preliminary Results 2024
|
RNS
|
|
21/10/2024
|
07:00
|
Commencement of Phase III Paediatric Trial
|
RNS
|
|
16/10/2024
|
07:00
|
Update on funding
|
RNS
|
|
01/10/2024
|
07:00
|
Update on funding and preliminary results
|
RNS
|
|
17/09/2024
|
07:00
|
Progression of patient cohorts in PROTECT Trial
|
RNS
|
|
27/08/2024
|
07:00
|
Update on funding
|
RNS
|
|
22/07/2024
|
07:00
|
Appointment of Nominated Adviser and Sole Broker
|
RNS
|
|
22/07/2024
|
07:01
|
Trading update for the year ended 30 June 2024
|
RNS
|
|
04/07/2024
|
14:22
|
Launch of new Company Long Term Incentive Plan
|
RNS
|
|
27/06/2024
|
07:00
|
Appointment of Non-Executive Director
|
RNS
|
|
10/06/2024
|
07:00
|
Progression of patient cohorts in PROTECT Trial
|
RNS
|
|
03/06/2024
|
07:00
|
Successful meetings with Paul Ehrlich Institut
|
RNS
|
|
07/05/2024
|
07:00
|
Further detail from G306 Phase III field trial
|
RNS
|
|
03/04/2024
|
07:00
|
Director Resignation
|
RNS
|
|
27/03/2024
|
07:00
|
Update on funding
|
RNS
|
|
27/03/2024
|
07:00
|
Interim Results for six months ended 31 Dec 2023
|
RNS
|
|
12/03/2024
|
08:59
|
VLP Peanut PROTECT Trial Update
|
RNS
|
|
11/03/2024
|
07:00
|
Appointment of Shaun Furlong to Board of Directors
|
RNS
|
|
08/03/2024
|
13:49
|
Result of AGM
|
RNS
|
|
14/02/2024
|
07:00
|
Half-Year Trading Update 2024
|
RNS
|
|
09/02/2024
|
15:07
|
Notice of 2023 Annual General Meeting
|
RNS
|
|
30/01/2024
|
07:30
|
Restoration - Allergy Therapeutics plc
|
RNS
|
|
30/01/2024
|
07:00
|
Publication of Annual Report and Accounts 2023
|
RNS
|
|
04/01/2024
|
12:29
|
Total Voting Rights
|
RNS
|
|
02/01/2024
|
07:30
|
Suspension - Allergy Therapeutics plc
|
RNS
|
|
27/12/2023
|
12:01
|
Amendment to existing Facility Agreement
|
RNS
|